

Resource Summary Report

Generated by SPARC SAWG on Sep 12, 2026

MassLynx

RRID:SCR_014271

Type: Tool

Proper Citation

MassLynx (RRID:SCR_014271)

Resource Information

URL: http://www.waters.com/waters/en_US/MassLynx-MS-Software/nav.htm?cid=513662&locale=en_US

Proper Citation: MassLynx (RRID:SCR_014271)

Description: Software which can acquire, analyze, manage, and share mass spectrometry data. MassLynx controls any Waters mass spectrometry system, from sample and solvent management components to mass spectrometer and auxiliary detectors. The software can acquire nominal mass, exact mass, MS/MS and exact mass MS/MS data. The software system also maintains and consolidates all user sample data. Optional Application Manager programs provide additional information for specific MS analyses and data., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Synonyms: MassLynx MS Software

Resource Type: data acquisition software, data analysis software, data management software, data processing software, software application, software resource

Keywords: data acquisition software, data analysis software, data management software, mass spectrometry

Availability: THIS RESOURCE IS NO LONGER IN SERVICE

Resource Name: MassLynx

Resource ID: SCR_014271

License URLs: http://www.waters.com/waters/en_US/Terms-of-Use/nav.htm?locale=en_US&cid=1000245 http://www.waters.com/waters/en_US/Site-Copyright/nav.htm?locale=en_US&cid=1001022

Record Creation Time: 20220129T080319+0000

Ratings and Alerts

No rating or validation information has been found for MassLynx .

No alerts have been found for MassLynx .

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 5809 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Lesire L, et al. (2026) Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma. British journal of pharmacology, 183(12), 3355.

Kawase M, et al. (2026) Phospholipid flippases ATP8A1 and ATP8A2 regulate GABAA receptor trafficking through distinct mechanisms in hippocampal neurons. iScience, 29(7), 116626.

Pan CH, et al. (2026) Mitochondrial-Localized Keratin 17 Promotes Chemoresistance in Basal-like Pancreatic Cancer. Cancer research, 86(12), 2935.

Aufdermauer J, et al. (2026) Cancer-Associated BCL-2 Mutants Reveal Mechanisms Towards Venetoclax Resistance. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e76693.

Nikhil J, et al. (2026) Kynurenine Pathway Metabolite Levels in Drug Naïve and Risperidone Treated Schizophrenia: Insights From Systemic and Post-Mortem Brain Tissue Analysis. Journal of neurochemistry, 170(6), e70504.

Xiao W, et al. (2026) Metabolite-gated vascular contractility switch: OXGR1 activation mechanism enables agonist therapy for rosacea erythema. Cell, 189(7), 1990.

Tiwari D, et al. (2026) Molecular mechanisms of naturally encoded signaling bias at the complement anaphylatoxin receptors. Molecular cell, 86(13), 2586.

Zhen Q, et al. (2025) Erucic Acid, Derived by Lactobacillus Crispatus, Induces Ferroptosis in Cervical Cancer Organoids Through the PPAR-? Signaling Pathway. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 12(48), e12599.

Huang Y, et al. (2025) Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD. Cell reports. Medicine, 102522.

Guignet M, et al. (2025) Challenging the preclinical paradigm: Adverse effects of antiseizure medicines in male rats with drug-resistant epilepsy. *British journal of pharmacology*, 182(18), 4314.

Wang K, et al. (2025) Tobacco Smoking Rewires Cell Metabolism by Inducing GAPDH Succinylation to Promote Lung Cancer Progression. *Cancer research*, 85(15), 2838.

Petrova ZO, et al. (2025) The role of kinase domain dimerization in EGFR activation. *Structure (London, England : 1993)*.

Jiang J, et al. (2025) Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism. *Cell metabolism*, 37(5), 1119.

Tsimberidou AM, et al. (2025) Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(6), 965.

Beck O, et al. (2025) Volumetric dried blood spots for determination of phosphatidylethanol: Validation of a liquid chromatography tandem massspectrometry method and clinical application. *Drug testing and analysis*, 17(2), 231.

Simkhada B, et al. (2025) A Drosophila model of mucopolysaccharidosis IIIB. *Genetics*, 229(3).

Burban A, et al. (2025) Exploiting metabolic vulnerability in glioblastoma using a brain-penetrant drug with a safe profile. *EMBO molecular medicine*, 17(3), 469.

Yao T, et al. (2025) Relationship between secondary metabolites and ecological suitability zones for *Eucommia ulmoides*. *PloS one*, 20(1), e0317368.

Wolf P, et al. (2025) Mineralocorticoid axis activity and cardiac remodeling in patients with ACTH-dependent Cushing's syndrome. *Endocrine connections*, 14(2).

Czabajszki M, et al. (2025) Altered Pattern of Serum N-Glycome in Subarachnoid Hemorrhage and Cerebral Vasospasm. *Journal of clinical medicine*, 14(2).